Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
In the register
The register attaches this trial to Jaktinib (Suzhou Zelgen Biopharmaceuticals), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Participants (registry)
- 315
- Start
- March 2022
- Primary completion
- June 2024
- Study completion
- June 2024
- Last registry update
- March 2025
- Countries
- China
Conditions studied: Alopecia Areata
Interventions: Jaktinib
Other trials of Jaktinib
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.